Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to advance the development of novel drugs targeting G protein-coupled receptors (GPCRs), ion channels, transporters, and other integral membrane proteins, focusing on treatment areas such as mental health and cardio-renal-metabolic diseases.
Collaboration Details
Under the agreement, Salipro Biotech’s proprietary Salipro platform technology will be utilized to enable the use of membrane proteins in their native forms for drug discovery programs. Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), to identify potential therapeutic candidates. This integrated approach leverages Salipro’s innovative platform and Boehringer Ingelheim’s extensive drug development expertise.
Financial Terms
Salipro Biotech will receive undisclosed research payments and option payments under the agreement. The company is also eligible for downstream success-based milestone payments, reflecting the potential value of the collaboration in advancing novel therapeutics.-Fineline Info & Tech
Leave a Reply